ClinicalTrials.Veeva

Menu

A Retrospective Study to Evaluate the Clinical Outcome According to Treatment in aHUS Patients in South Korea

H

Handok

Status

Completed

Conditions

aHUS

Study type

Observational

Funder types

Industry

Identifiers

NCT05405777
HD-ECU-501

Details and patient eligibility

About

Primary objective

  • To determine the clinical prognosis by identifying the disease course and severity by treatment with or without eculizumab in patients with aHUS in Korea.

Secondary objectives

  • To determine the clinical prognosis of the disease in all patients with aHUS in Korea.
  • To determine the clinical prognosis of the disease in patients diagnosed with aHUS prior to the initiation of eculizumab reimbursement system in Korea.
  • To determine the treatment responses by treatment options in patients with aHUS in Korea.
  • To identify risk factors that affect mortality in all patients with aHUS in Korea.
  • To investigate the recurrence and clinical prognosis in patients with aHUS in Korea when eculizumab is discontinued

Full description

As a retrospective, non-interventional, multi-center study

Enrollment

97 patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients who are clinically diagnosed with the aHUS

Exclusion criteria

  • Patients who are diagnosed with Shiga toxin-producing E. coli hemolytic-uremic syndrome (STEC-HUS).
  • Patients with less than 10% in a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS-13) activity test

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems